Only days after the Food and Drug Administration cleared Diatide's acute venous thrombosis imaging agent AcuTect (SCAN 9/30/98), the Londonderry, NH, radiopharmaceutical firm received a $2 million milestone payment from marketing partner Nycomed Amersham
Only days after the Food and Drug Administration cleared Diatide's acute venous thrombosis imaging agent AcuTect (SCAN 9/30/98), the Londonderry, NH, radiopharmaceutical firm received a $2 million milestone payment from marketing partner Nycomed Amersham of Buckinghamshire, U.K. The cash is the second payment Diatide has received from Nycomed Amersham in the last two months: In August, Diatide received $2 million for filing a new drug application for NeoTect, its lung cancer imaging agent.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.